SCHEMBL31666079

SCHEMBL31666079

O=C(O)c1c2c(nc3cc(Cl)ccc13)CCN(CCc1ccccc1)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.48
▸ TP53 P04637 2/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ MAPT P10636 5/20 0.47
▸ POLB P06746 3/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ TDP1 Q9NUW8 3/20 0.47
▸ RECQL P46063 1/20 0.47
▸ CASP6 P55212 1/20 0.47
▸ MEN1 O00255 1/20 0.45
▸ PTPN2 P17706 1/20 0.45
▸ PTPN1 P18031 1/20 0.45
▸ ACHE P22303 1/20 0.44
▸ LMNA P02545 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26098464 1.00 ALDH1A1 (0.48) ALDH1A1TP53MAPK1SMN1; SMN2KMT2A
SCHEMBL31666080 0.93 TDP1 (0.56) ALDH1A1TP53MAPK1SMN1; SMN2KMT2A
SCHEMBL26100476 0.93 TDP1 (0.56) ALDH1A1TP53MAPK1SMN1; SMN2KMT2A
SCHEMBL26099638 0.90 ALDH1A1 (0.54) ALDH1A1TP53MAPK1SMN1; SMN2KMT2A
SCHEMBL26098455 0.88 ALDH1A1 (0.56) ALDH1A1TP53MAPK1SMN1; SMN2KMT2A
SCHEMBL31666083 0.88 ALDH1A1 (0.56) ALDH1A1TP53MAPK1SMN1; SMN2KMT2A
SCHEMBL26097193 0.88 MAPT (0.57) ALDH1A1TP53MAPK1SMN1; SMN2KMT2A
SCHEMBL26099566 0.86 LMNA (0.56) ALDH1A1TP53MAPK1SMN1; SMN2KMT2A
SCHEMBL26097738 0.85 MAPT (0.54) ALDH1A1TP53MAPK1SMN1; SMN2KMT2A
SCHEMBL26098861 0.84 MAPT (0.51) ALDH1A1TP53MAPK1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12370183-B2 Compositions and methods for treating malaria RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-07-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12370183-B2 Compositions and methods for treating malaria G6PD, QDPR, FASN ALDH1A1 1569/4885TP53 4568/4885MAPK1 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback